<DOC>
	<DOCNO>NCT01782352</DOCNO>
	<brief_summary>The VITamin D OmegA-3 Trial ( VITAL ; NCT 01169259 ) randomize clinical trial 25,875 U.S. men woman investigate whether take daily dietary supplement vitamin D3 ( 2000 IU ) omega-3 fatty acid ( Omacor fish oil , 1 gram ) reduce risk develop cancer , heart disease , stroke people prior history illness . This ancillary study conduct among participant VITAL examine whether vitamin D omega-3 fatty acid , compare placebo , reduce incidence and/or progression age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>Age-related Macular Degeneration ( AMD ) Vitamin D Omega-3 Trial ( VITAL )</brief_title>
	<detailed_description>This ancillary study VITamin D OmegA-3 TriaL ( VITAL ) examine whether vitamin D3 omega-3 fatty acid help prevent onset progression age-related macular degeneration ( AMD ) . The study also examine whether vitamin D3 omega-3 fatty acid interact , specific gene associate AMD vitamin D3 omega-3 fatty acid metabolic activity , affect risk develop AMD .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>All participant VITAL ( NCT 01169259 ) eligible participate ancillary study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>age-related macular degeneration</keyword>
	<keyword>incidence</keyword>
	<keyword>progression</keyword>
</DOC>